Integra LifeSciences Holdings Balance Sheet Health
Financial Health criteria checks 2/6
Integra LifeSciences Holdings has a total shareholder equity of $1.6B and total debt of $1.9B, which brings its debt-to-equity ratio to 116.3%. Its total assets and total liabilities are $4.1B and $2.5B respectively. Integra LifeSciences Holdings's EBIT is $239.7M making its interest coverage ratio 6.9. It has cash and short-term investments of $677.3M.
Key information
116.3%
Debt to equity ratio
US$1.86b
Debt
| Interest coverage ratio | 6.9x |
| Cash | US$677.29m |
| Equity | US$1.60b |
| Total liabilities | US$2.48b |
| Total assets | US$4.08b |
Recent financial health updates
We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt
Feb 11
Does Integra LifeSciences Holdings (NASDAQ:IART) Have A Healthy Balance Sheet?
Nov 06These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well
Apr 07We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt
Jan 05We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt
Oct 05Recent updates
At US$29.14, Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Worth Looking At Closely?
Jul 01Integra LifeSciences Still Underperforming As Manufacturing Issues Linger
Jun 21Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Intrinsic Value Is Potentially 40% Above Its Share Price
May 28Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Stalled
Feb 27We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt
Feb 11Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Jan 14Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Price In Tune With Earnings
Dec 31Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 46% Discount?
Dec 03Does Integra LifeSciences Holdings (NASDAQ:IART) Have A Healthy Balance Sheet?
Nov 06Integra LifeSciences Holdings (NASDAQ:IART) Hasn't Managed To Accelerate Its Returns
Oct 24Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Sep 22Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 38% Discount?
Aug 15Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Hit The Brakes
Jul 03Is There Now An Opportunity In Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Jun 19Estimating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)
May 05These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well
Apr 07Integra LifeSciences Holdings (NASDAQ:IART) Is Experiencing Growth In Returns On Capital
Mar 26At US$52.61, Is It Time To Put Integra LifeSciences Holdings Corporation (NASDAQ:IART) On Your Watch List?
Mar 14Does Integra LifeSciences Holdings (NASDAQ:IART) Deserve A Spot On Your Watchlist?
Feb 27Calculating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)
Feb 02We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt
Jan 05Here's What To Make Of Integra LifeSciences Holdings' (NASDAQ:IART) Decelerating Rates Of Return
Dec 21When Should You Buy Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Dec 08Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 42% Discount?
Oct 19We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt
Oct 05Integra LifeSciences: Wide Dislocation In Fundamentals Vs. Market Value
Sep 13Is It Time To Consider Buying Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Sep 06FDA labels recall of intracranial pressure monitors by Integra as most serious
Aug 31Integra Lifesciences voluntarily recalls pressure monitors, lowers revenue, profit guidance
Aug 24Returns At Integra LifeSciences Holdings (NASDAQ:IART) Appear To Be Weighed Down
Aug 23Financial Position Analysis
Short Term Liabilities: IART's short term assets ($1.4B) exceed its short term liabilities ($302.4M).
Long Term Liabilities: IART's short term assets ($1.4B) do not cover its long term liabilities ($2.2B).
Debt to Equity History and Analysis
Debt Level: IART's net debt to equity ratio (73.9%) is considered high.
Reducing Debt: IART's debt to equity ratio has increased from 99.1% to 116.3% over the past 5 years.
Debt Coverage: IART's debt is not well covered by operating cash flow (7%).
Interest Coverage: IART's interest payments on its debt are well covered by EBIT (6.9x coverage).